A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Phase 1 Completed 46 enrolled Satsuma Pharmaceuticals, Inc.

RandomizedCrossoverOpen-labelTreatment

Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.

Evaluation	Drug	Modality	Dose	Route
Subject	Dihydroergotamine	Small molecule	1 mg	Intranasal
Subject	Dihydroergotamine	Small molecule	1.5 mg	Intranasal
Subject	Dihydroergotamine	Small molecule	2 mg	Intranasal
Subject	Dihydroergotamine	Small molecule	3 mg	Intranasal
Subject	Dihydroergotamine	Small molecule	6 mg	Intranasal